A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas.

Trial Profile

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Bortezomib (Primary) ; Vorinostat (Primary)
  • Indications CNS cancer; Lymphoma; Sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 14 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 06 Apr 2011 Status changed from recruiting to active, no longer recruiting.
    • 27 May 2010 New source identified and integrated (NCT01132911).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top